Birkmayer J G, Vrecko C, Volc D, Birkmayer W
Birkmayer-Institut für Parkinsontherapie Vienna, Austria.
Acta Neurol Scand Suppl. 1993;146:32-5.
The reduced coenzyme nicotinamide adenine dinucleotide (NADH) has been used as medication in 885 parkinsonian patients in an open label trial. About half of the patients received NADH by intravenous infusion, the other part orally by capsules. In about 80% of the patients a beneficial clinical effect was observed: 19.3% of the patients showed a very good (30-50%) improvement of disability, 58.8% a moderate (10-30%) improvement. 21.8% did not respond to NADH. Statistical analysis of the improvement in correlation with the disability prior to treatment, the duration of the disease and the age of the patients revealed the following results: All these 3 parameters have a significant although weak influence on the improvement. The disability before the treatment has a positive regression coefficient (t value < 0.01). The duration of the disease has a negative regression coefficient (< 0.01) and so has the age a negative regression coefficient (t value < 0.05). In other words younger patients and patients with a shorter duration of disease have a better chance to gain a marked improvement than older patients and patients with longer duration of the disease. The orally applied form of NADH yielded an overall improvement in the disability which was comparable to that of the parenterally applied form.
在一项开放标签试验中，还原型辅酶烟酰胺腺嘌呤二核苷酸（NADH）已被用作885例帕金森病患者的药物。约一半患者通过静脉输注接受NADH，另一半通过口服胶囊接受。约80%的患者观察到有益的临床效果：19.3%的患者残疾状况有非常好（30 - 50%）的改善，58.8%有中度（10 - 30%）的改善。21.8%的患者对NADH无反应。对改善情况与治疗前残疾状况、病程和患者年龄相关性的统计分析得出以下结果：所有这三个参数对改善均有显著但微弱的影响。治疗前的残疾状况有正回归系数（t值<0.01）。病程有负回归系数（<0.01），年龄也有负回归系数（t值<0.05）。换句话说，年轻患者和病程较短的患者比老年患者和病程较长的患者有更好的机会获得显著改善。口服形式的NADH在残疾状况改善方面产生的总体效果与胃肠外给药形式相当。
